Table 3.
Table3. Hazard ratios (95% confidence interval) of incident total and ischemic stroke associated with progression of valvular calcification, MESA, 2000–2016
| Progressors vs non-progressors | ||
|---|---|---|
| Aortic valve calcium | Mitral annular calcium | |
| Total stroke, n (%)Progressors vs non-progressors | 31 (5.6) vs 180 (3.6) | 41 (7.4) vs 170 (3.4) |
| N Progressors vs non-progressors | 556 vs 4983 | 557 vs 4982 |
| Model 1 | 1.11 (0.75 – 1.64) | 1.64 (1.15 – 2.35) |
| Model 2 | 1.10 (0.74 – 1.62) | 1.66 (1.16 – 2.38) |
| Model 3 | 1.02 (0.69 – 1.52) | 1.59 (1.11 – 2.28) |
| Model 4 | 0.96 (0.65 – 1.44) | 1.48 (1.03 – 2.13) |
| Ischemic stroke, n (%)Progressors vs non-progressors | 27 (4.9) vs 140 (2.8) | 34 (6.2) vs 133 (2.7) |
| N Progressors vs non-progressors | 552 vs 4943 | 550 vs 4945 |
| Model 1 | 1.20 (0.78 – 1.83) | 1.74 (1.17 – 2.58) |
| Model 2 | 1.17 (0.77 – 1.80) | 1.73 (1.16 – 2.57) |
| Model 3 | 1.07 (0.70 – 1.64) | 1.64 (1.10 – 2.45) |
| Model 4 | 1.01 (0.66 – 1.55) | 1.53 (1.02 – 2.29) |
Fonts in bold are statistically significant, p<0.05.
Model 1: age, race/ethnicity, sex, MESA site, CT scanner type.
Model 2: Model 1+ educational status, BMI, smoking status, pack-years of smoking, and physical activity.
Model 3: Model 2 + systolic blood pressure, diastolic blood pressure, use of antihypertensives, use of lipid lowering medications, total cholesterol, HDL-cholesterol, LDL-cholesterol, diabetes status and eGFR.
Model 4: Model 3 + baseline coronary calcium.
Progressors: participants with >0 Agatston units of change/year between CT scans
Non-progressors: participants with ≤0 Agatston units of change/year between CT scans